Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to JanssenBARDA award to support expanded manufacturing and clinical development of CD388FDA granted Breakthrough Therapy designation to CD388Conference call and webcast today at 5:00 PM Eastern T ...